Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. In this paper, Byoung Dae Lee1, Joo-Ho Shin1, Jackalina VanKampen, Leonard Petrucelli, Andrew B West1, Han Seok Ko1, Yun-Il Lee1, Kathleen A Maguire-Zeiss, William J Bowers, Howard J Federoff, Valina L Dawson1 & Ted M Dawson have identified inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. The results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
|